scholarly journals Frequency and Associations of Prescription Nonsteroidal Anti-inflammatory Drug Use Among Patients With a Musculoskeletal Disorder and Hypertension, Heart Failure, or Chronic Kidney Disease

2018 ◽  
Vol 178 (11) ◽  
pp. 1516 ◽  
Author(s):  
Zachary Bouck ◽  
Graham C. Mecredy ◽  
Noah M. Ivers ◽  
Moumita Barua ◽  
Danielle Martin ◽  
...  
2011 ◽  
Vol 9 (5) ◽  
pp. 423-430 ◽  
Author(s):  
L. Plantinga ◽  
V. Grubbs ◽  
U. Sarkar ◽  
C.-y. Hsu ◽  
E. Hedgeman ◽  
...  

2016 ◽  
Vol 30 (6) ◽  
pp. 781-786 ◽  
Author(s):  
Zbigniew Heleniak ◽  
Magdalena Cieplińska ◽  
Tomasz Szychliński ◽  
Dymitr Rychter ◽  
Kalina Jagodzińska ◽  
...  

Author(s):  
O. Zubl ◽  
W. Roborchuks ◽  
G. Dotsyukl

 The purpose - to investigate the effect of aceclofenac on the level of proand anti - inflammatory cytokines in patients with rheumatoid arthritis and chronic kidney disease. Material and Methods: The research included 88patients: 45 with rheumatoid arthritis (RA) without chronic kidney disease (CKD), 43 with RA and CKD stage I without nephrotic syndrome. In a complex therapie of patients it is included nonsteroid anti - inflammatory drug aceclofenac. Influence of aceclofenac was compared with meloxicam. It is investigated to patients the content IL - 1$, IL - 10, TNFa, TGF$1, MCP - 1 is the urine with an immunofermental method. Results. After two weeks of therapy with aceclofenac was revealed reduction IL - 1$ levels (p<0,05) and urinary (p<0,05), TNFa levels (p<0,05) in patients with RA and RA with CKD. Level of pro - sclerous cytokin TGFf>1 of blood (p<0,05) and urine (p<0,001) at patients with RA with CKD is reduced. Decrease in the MCP - 1 level in blood (in 1,5 times) and in urine (in 2 times) at patients with RA and CKD is revealed. Conclusion. Application of therapy with aceclofenac for complex treatment ofpatients with RA and CKD improves efficiency of treatment for these patients through improvement cytokines of blood and urine.  


2020 ◽  
Vol 75 (11) ◽  
pp. 909
Author(s):  
Thiratest Leesutipornchai ◽  
Thanaporn Ratchataswan ◽  
Palapun Waitayangkoon ◽  
Aunchalee Jaroenlapnopparat ◽  
Supanee Sinphurmsukskul ◽  
...  

Author(s):  
Bethany S. Ward ◽  
Michael Naughton ◽  
Dorothea Nitsch ◽  
Mariam Molokhia

Abstract Aim To examine the risk of non-steroidal anti-inflammatory drug-induced heart failure in patients with chronic kidney disease. Methods Embase, Medline, CENTRAL, Web of Science, and Google Scholar were searched for papers published in English between 1st January 1999 and 31st May 2020. Papers were included if some participants had chronic kidney disease, were exposed to non-steroidal anti-inflammatory drugs, and where heart failure was measured as an outcome. Papers were assessed for risk of bias using the Cochrane Risk of Bias 2 tool for randomised controlled trials, and ROBINS-I for observational studies. Results A total of 2480 independent papers were retrieved. Following abstract screening, 165 full texts were reviewed to identify seven eligible papers: two randomised controlled trials, four cohort studies, and one case-control study. For chronic kidney disease (stage 3–5), relative risk for heart failure ranged from 0.3 to 1.9 with 95% confidence interval 0.04 to 15.1. Results were not pooled due to study heterogeneity. We attributed bias to heterogenous populations studied, probable confounding due to partially adjusted risk estimates, and heterogenous measurement of the heart failure outcome. Conclusion Overall, there are only a few studies to refute or support an increased risk of heart failure associated with taking non-steroidal anti-inflammatory drugs in patients with chronic kidney disease, and therefore no robust evidence was available.


Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1130-P
Author(s):  
JINGWEI LI ◽  
BRUCE NEAL ◽  
HIDDO L. HEERSPINK ◽  
CLARE ARNOTT ◽  
CHRISTOPHER CANNON ◽  
...  

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 27-OR
Author(s):  
JINGWEI LI ◽  
MEG J. JARDINE ◽  
BRUCE NEAL ◽  
HIDDO L. HEERSPINK ◽  
CHRISTOPHER CANNON ◽  
...  

2017 ◽  
pp. 101-106
Author(s):  
Thi Thanh Hien Bui ◽  
Hieu Nhan Dinh ◽  
Anh Tien Hoang

Background: Despite of considerable advances in its diagnosis and management, heart failure remains an unsettled problem and life threatening. Heart failure with a growing prevalence represents a burden to healthcare system, responsible for deterioration of patient’s daily activities. Galectin-3 is a new cardiac biomarker in prognosis for heart failure. Serum galectin-3 has some relation to heart failure NYHA classification, acute coronary syndrome and clinical outcome. Level of serum galectin-3 give information for prognosis and help risk stratifications in patient with heart failure, so intensive therapeutics can be approached to patients with high risk. Objective: To examine plasma galectin-3 level in hospitalized heart failure patients, investigate the relationship between galectin-3 level with associated diseases, clinical conditions and disease progression in hospital. Methodology: Cross sectional study. Result: 20 patients with severe heart failure as NYHA classification were diagnosed by The ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (2012) and performed blood test for serum galectin-3 level. Increasing of serum galectin-3 level have seen in all patients, mean value is 36.5 (13.7 – 74.0), especially high level in patient with acute coronary syndrome and patients with severe chronic kidney disease. There are five patients dead. Conclusion: Serum galectin-3 level increase in patients with heart failure and has some relation to NYHA classification, acute coronary syndrome. However, level of serum galectin-3 can be affected by severe chronic kidney disease, more research is needed on this aspect Key words: Serum galectin-3, heart failure, ESC Guidelines, NYHA


Sign in / Sign up

Export Citation Format

Share Document